Market Research Life Sciences Market Research Diagnostics Market Research In Vitro Diagnostics Market Research Coagulation Market Research

IVD Test Procedure Volumes, 2024-2029

Best Price Guarantee Length Publisher Published Date SKU
from $6,300 405 Pages Kalorama Information October, 2024 KLI19223987
Best Price Guarantee
Price from $6,300
Length 405 Pages
Publisher Kalorama Information
Published Date October, 2024
SKU KLI19223987

IVD Test Procedure Volumes, 2024-2029


Kalorama Information's IVD Test Procedure Volumes, 2024-2029 report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama’s comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.

As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.

With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, IVD Test Procedure Volumes, 2024-2029 offers the data and insights you need to succeed.

Why Choose This Report?
  • Comprehensive Market Data
Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond—this report covers it all.
  • Unmatched Insights into Growth Opportunities
    • Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.
  • Forward-Looking Analysis
    • Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.
  • Strategic Guidance for Industry Players
    • Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.
Scope & Methodology

The report includes:
  • Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
  • Regional and Country-Specific Data for IVD procedures and their projected growth rates.
  • Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.


  • Executive Summary
    • IVD Procedure Volume Estimate and Forecast
      • Table Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
    • Scope & Methodology
    • About Kalorama Information
  • Introduction
    • Overview
    • Industry Trends
      • Table Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
      • Table Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
    • Demographic Trends
      • Global Population and Aging
        • Table Global Fertility Rate vs. Population Size, 1950-2050 (billion)
        • Table Global Population Distribution, 2022
        • Table Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
      • Workforce Reduction
        • Table Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
    • Increase in Chronic Diseases
      • Table Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
    • Personalized Medicine
    • New Infectious Disease Threats
      • Table Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
      • Tickborne Diseases (TBDs)
      • Zika
      • Chagas
      • Dengue
      • Ebola
      • Chikungunya
      • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
      • Marburg
      • SARS-CoV-2 (COVID-19)
      • Monkeypox
        • Table Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
    • Emerging and Emerged Markets
      • Table Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)
  • IVD Testing Segments
    • IVD Testing Trends
      • Table IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
    • Segment Growth Projections
      • POC Testing
        • Table POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
        • Table POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
      • Clinical Chemistry
        • Table Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Immunoassays
        • Table Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Mass Spectrometry (Immuno)
        • Table Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Molecular Assays
        • Table Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Hematology
        • Table Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Coagulation
        • Table Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Conventional Microbiology
        • Table Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Blood Grouping/Typing
        • Table Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
      • Histology/Cytology
        • Table Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
        • Table Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
    • Segment Product Sales
      • Table IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
      • Table IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Global IVD Markets
    • General
      • Table IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, &South America; Middle East; North America [United States; Canada]; Western Europe)
      • Table IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
      • Table IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
      • Table IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
    • North America
      • Table North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
      • Table North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
      • United States
      • Canada
    • Mexico, Central & South America
      • Table Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
      • Table Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024- 2029 (millions)
      • Brazil
      • Mexico
      • Other Central & South America
    • Western Europe
      • Table Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024- 2029 (millions) (%)
      • Table Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
      • Other Western Europe
    • Eastern Europe
      • Table Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024- 2029 (millions) (%)
      • Table Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
      • Russia
      • Other Eastern Europe
    • Asia/Pacific
      • Table Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
      • Table Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
      • China
      • Japan
      • Other Asian Countries and Territories
    • Middle East
      • Table Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
      • Table Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
      • Turkey
      • Other Middle East
    • Africa
      • Table Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
      • Table Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Point-of-Care (POC) Procedures
    • Global POC Procedure Volume by Test Type
      • Table Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
      • Table Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
      • Table Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)
    • POC Self Tests
      • Table POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
      • Traditional Blood Glucose Monitoring Activities
      • Continuous Blood Glucose Monitoring
      • Pregnancy and Fertility Testing
      • Coagulation Testing
      • Fecal Occult Blood Testing
      • Drugs of Abuse Testing
      • H. Pylori Testing
      • HIV Testing
      • Infectious Disease
      • Cholesterol Testing
      • POC Urinalysis Testing
      • Other POC Self-Testing
    • POC Self-Testing Product Sales
      • Table POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
    • Pricing Trends
      • Table POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
    • POC Professional Testing
      • Table POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
      • POC Professional Blood Glucose Testing Procedures
      • POC Professional Critical Care Testing
      • POC Fertility Testing
      • POC Professional Infectious Disease Testing
      • POC Professional Cardiac Marker Testing
      • POC Professional Cholesterol/Lipid Testing
      • POC Professional Coagulation Testing
      • POC Professional HbA1C Testing
      • POC Professional Hematology Testing
      • POC Professional Fecal Occult Blood Screening
      • POC Professional Drugs of Abuse Testing
      • POC Professional Urinalysis Testing
      • Other POC Professional Testing
    • POC IVD Product Sales
      • Table POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
    • Pricing Trends
      • Table POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
  • Clinical Chemistry Procedures
    • Table Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
    • Table Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
    • Types of Tests
      • General Chemistry
      • Blood Gases & Electrolytes
      • Urinalysis
    • Global Sales of Clinical Chemistry Products
      • Table Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)
    • Pricing Trends
      • Table Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)
  • Immunoassay Procedures
    • Technologies
    • Labeling Techniques
      • Enzyme Immunoassays
      • Fluorescence Polarization Immunoassays (FPIAs)
      • Radioimmunoassays (RIAs)
        • Table Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
        • Table Regional Immunoassay Procedure Volumes, 2024
    • Testing Procedures & Product Sales
      • Table Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
      • Cardiac Markers
      • Tumor Markers
      • Autoimmune Conditions
      • Allergy Conditions
      • Thyroid Conditions
      • Proteins
      • Anemia
      • Fertility Testing
      • Therapeutic Drug Monitoring
      • Vitamin D
      • Diabetes/HbA1c
      • Drugs of Abuse
      • Infectious Diseases
        • Table Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
        • Table Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
    • Instruments
    • Pricing Trends
      • Table Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
  • Molecular Testing Procedures
    • Table Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
    • Table Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
    • Types of Tests
      • Testing Technologies
      • Infectious Diseases
        • Table Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
      • Blood Screening
      • Cancer
      • Transplant Matching
      • Thrombophilia SNPs
      • Inherited Diseases
      • Other Molecular Tests
      • Prenatal
    • Global Sales of Molecular IVD Products
      • Table Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
      • Table Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
    • Pricing Trends
      • Table Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
  • Laboratory-Based Hematology Procedures
    • Table Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
    • Table Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
    • Types of Tests
    • Global Sales of Hematology Products
      • Table Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)
    • Pricing Trends
      • Table Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)
  • Coagulation Testing Procedures
    • Table Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
    • Table US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
    • Types of Tests
    • Global Sales of Coagulation Products
      • Table Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)
    • Pricing Trends
      • Table Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)
  • Microbiology Procedures
    • Table Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
    • Table Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
    • Types of Tests
      • ID/AST Automated Panels & Reagents
      • Manual Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
    • Global Sales of Conventional IVD Microbiology Products
      • ID/AST Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
        • Table Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
    • Pricing Trends
      • Table Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
  • Blood Grouping/Typing Procedures
    • Table Blood Grouping/Typing Procedure Volumes, 2024-2029
    • Table Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
    • Types of Tests
    • Blood Grouping/Typing Product Sales
      • Table Blood Grouping/Typing Product Sales, 2024-2029 ($ million)
    • Pricing Trends
      • Table Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029
  • Histology/Cytology Procedures
    • Table Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
    • Table Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
    • Types of Tests
      • Immunohistochemistry Tests
      • In Situ Hybridization Tests
      • Pap Tests
      • Traditional Non-Pap Stains
      • Circulating Tumor Cells
      • Flow Cytometry
    • Histology/Cytology IVD Product Sales
      • Table Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
    • Pricing Trends
      • Table Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029
  • Company Profiles
    • Table Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMérieux; Bio-Rad Laboratories; Bruker – CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)
    • Abbott Diagnostics
      • Recent Revenue History
        • Table Abbott Diagnostic Revenues, 2017-2023 (million $)
      • Core Lab
      • Hematology
      • Blood Banking
      • Infectious Diseases - Molecular
      • Diabetes
      • HIV Point of Care
      • i-STAT Business
      • COVID-19
    • Agilent Technologies
      • Recent Revenue History
        • Table Agilent Revenues, 2017-2023 (million $)
      • Agilent in Genomics
      • Cytogenetic Analysis
      • Sequencing
      • Flow Cytometry
      • Companion Diagnostics - Dako
      • COVID-19
    • Becton, Dickinson and Company (BD)
      • Recent Revenue History
        • Table BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30
      • Cytology
      • Molecular Microbiology
      • Traditional Microbiology - ID/AST
      • Blood Culture
      • Hospital Acquired Infections
      • Blood Collection
      • Mass Spectrometry
      • COVID-19
    • bioMérieux Inc.
      • Recent Revenue History
        • Table bioMérieux IVD Revenues, 2017-2023 (million $)
      • Traditional Microbiology
      • Blood Culture
      • Immunoassays
      • Mass Spectrometry
      • BioFire Diagnostics Business
      • COVID-19
    • Bio-Rad Laboratories, Inc.
      • Recent Revenue History
        • Table Bio-Rad Diagnostics Revenues, 2017-2023 (million $)
      • Blood Bank
      • Immunoassays
      • COVID-19
    • Bruker Corporation
      • Recent Revenue History
        • Table Bruker Revenue History Product Revenue, 2017-2023 ($ million)
      • Acquisitions and Collaborations
      • Mass Spectrometry
      • Microbiology
      • Molecular PCR
      • COVID-19
    • Danaher Corporation
      • Recent Revenue History
        • Table Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)
    • Dexcom
      • Recent Revenue History
        • Table Dexcom IVD Diagnostic Sales, 2017-2023 (million $)
    • DiaSorin
      • Recent Revenue History
        • Table DiaSorin Revenues, 2017-2023 (million $)
      • Immunoassays
      • Molecular
      • COVID-19
    • Exact Sciences
      • Recent Revenue History
        • Table Exact Sciences Revenues, 2017-2023 (million $)
      • COVID-19
    • Hologic, Inc.
      • Recent Revenue History
        • Table Hologic Revenues, 2017-2023 (million $)
      • PANTHER Molecular System
      • HIV Testing
      • Sexually Transmitted Infections
      • Infectious Diseases
      • Cytology
      • COVID-19
    • Illumina
      • Recent Revenue History
        • Table Illumina Diagnostics Revenues, 2017-2023 (million $)
      • COVID-19
    • Instrument Laboratory/ Werfen
      • Expansion
      • Coagulation
      • Acute Care
    • Natera
      • Recent Revenue History
        • Table Natera Revenue History 2017-2023 ($ million)
      • Prenatal Paternity Testing
    • QuidelOrtho Corporation
      • Recent Revenue History
        • Table QuidelOrtho Revenue History 2018-2023 ($ million)
      • Immunoassays
      • Rapid Immunoassays
      • The Solana Business
      • Molecular – Savanna
      • Blood Bank
      • COVID-19
    • Revvity
      • Table Revvity Revenue History 2021-2023 ($ million, estimated)
    • Roche Diagnostics
      • Recent Revenue History
        • Table Roche Diagnostics IVD Revenues, 2017-2023 (million $)
      • Hematology
      • Core Lab
      • Immunoassays
      • HIV
      • Core Molecular
      • Digital PCR
      • Diabetes Care
      • Coagulation
      • cobas Liat System – POC
      • HPV
      • Blood Bank
      • Transplant Medicine
      • Cancer Companion Testing
      • COVID-19
    • Siemens Healthineers (Siemens)
      • Recent Revenue History
        • Table Siemens Healthineers IVD Revenues, 2017-2023 (million $)
      • Immunoassays
      • Hematology
      • Molecular
      • Acute Care – POC
      • COVID-19
    • Sysmex Corporation
      • Recent Revenue History
        • Table Sysmex IVD Revenues 2018-2023 (million $) FY March 31
      • Hematology
      • Coagulation
      • Urinalysis
      • Immunoassays
      • Precision Medicine / Companion Test Diagnostics
      • Oncology
      • COVID-19
    • Thermo Fisher Scientific Inc.
      • Recent Revenue History
        • Table Thermo Fischer IVD Revenues, 2017-2023 (million $)
      • Immunoassays
      • Microbiology
      • Next Generation Sequencing
      • Molecular and qPCR
      • Mass Spectrometry
      • COVID-19
    • Werfen
      • Recent Revenue History
        • Table Werfen IVD Revenues, 2017-2023 (million $)
      • Hematology and Coagulation
      • Autoimmunity

$6,300
$9,450
$12,600

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings